You are here

Article Text

Article menu
Download PDFPDF
Letter
Shingles following infliximab infusion
  1. D C Baumgart,
  2. A U Dignass
  1. Universitätsklinikum Charité, Campus Virchow-Klinikum, Medizinische Fakultät der Humboldt-Universität zu Berlin, Medizinische Klinik mit Schwerpunkt Hepatologie und Gastroenterologie, D-13344 Berlin, Germany
  1. Correspondence to:
    Dr D C Baumgart, Charité-Campus Virchow-Klinikum, Humboldt-Universität zu Berlin, Hepatologie und Gastroenterologie, D-13344 Berlin, Germany;
    daniel.baumgart{at}charite.de

https://doi.org/10.1136/ard.61.7.661

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Infliximab is a chimeric IgG1κ monoclonal antibody that binds specifically to human tumour necrosis factor alpha (TNFα). Infliximab, in combination with methotrexate, is approved for reducing signs and symptoms and inhibiting the progression of structural damage in patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to methotrexate. It will also reduce the signs and symptoms of Crohn's disease in patients with moderately to severely active Crohn's disease who have had an inadequate response to conventional treatment …

    View Full Text